1. Stats
  2. USPTO
  3. TC 1600
  4. Group 1630
  5. Art Unit 1635
  6. Examiner Arieti

Examiner Arieti Ruth S

1635-ARIETI-RUTH-S

Employment Information

Art Unit:1635 — Drug, bio-affecting and body treating compositions
Group:1630 — Stem cells and cell culture and Nucleic Acid related therapy
Classes: 514 — Drug, bio-affecting and body treating compositions
536 — Organic compounds -- part of the class 532-570 series
424 — Drug, bio-affecting and body treating compositions
435 — Chemistry: molecular biology and microbiology
800 — Multicellular living organisms and unmodified parts thereof and related processes
703 — Data processing: structural design, modeling, simulation, and emulation
Phone:(571) 272-1293
Email:ruth.arieti@uspto.gov
Location:VA 22314
Title:Pat Examnr (Biology)
Service:4 years
Grade:GS-09

Grant Rate and Difficulty Ranking

96
3-Year Grant rate: 10% over 94 cases
Difficulty: Extremely Hard
Difficulty Percentile: 96th

With Examiner Arieti, you have a 10% chance of getting an issued patent by 3 years after the first office action. Examiner Arieti is an extremely hard examiner and in the 96th percentile across all examiners (with 100th percentile most difficult).

Grant Rate

Grant Rate Timeline

Below is the grant rate timeline for Examiner Arieti, where the timeline is relative to the date of the first office action. The three-year grant rate is the percentage of applications granted at three years after the first office action.

Comparison with Art Unit 1635

Examiner Arieti's grant rate is lower than that of Art Unit 1635 and lower than that of the USPTO.

Average Office Actions Per Grant
Examiner Arieti 1.9
Art Unit 1635 1.6

Interview Benefit

Grant Rate without Interview

Examiner Arieti has granted 5 of 85 cases without any applicant-requested interviews for a grant rate of 6%.

Grant Rate with Interview

Examiner Arieti has granted 4 of 9 cases with at least one applicant-requested interview for a grant rate of 44%.

Interview Benefit

With Examiner Arieti, conducting an interview increases your chance of getting a patent granted by 633%.

Recent Dispositions

Recent Dispositions

Number Title OA Rejections Status IFW
18516722 Compositions And Methods For The Targeting Of Pcsk9 Rejection information available with a Premium Stats subscription. See our pricing. Patented View
18976043 Composition For Regulating Production Of Interfering Ribonucleic Acid Patented View
17287665 Compositions And Methods Involving Aptamer Switch Polynucleotides Abandoned View
17204480 Oligonucleotides For Mapt Modulation Abandoned View
18881645 Micellar Nanoparticles And Uses Thereof Abandoned View
18582317 Composition For Regulating Production Of Interfering Ribonucleic Acid Patented View
18932078 Composition For Regulating Production Of Interfering Ribonucleic Acid Patented View
17996806 Compositions And Methods For Regulation Of Cell Activity Via Modulation Of Beta-Cytokine Activity Abandoned View
17275959 Rnai Agents For Inhibiting Expression Of 17beta-Hsd Type 13 (Hsd17b13), Compositions Thereof, And Methods Of Use Patented View
18791380 Advanced Rna Targeting (Arnatar) Abandoned View
17268654 Nucleic Acids And Nucleic Acid Analogs For Treating, Preventing, And Disrupting Pathological Polynucleotide-Binding Protein Inclusions Patented View
18854299 Compositions And Methods For Treating Liver Diseases With Sirnas Targeting Tbx3 Abandoned View
18977470 Composition For Regulating Production Of Interfering Ribonucleic Acid Patented View
18977518 Composition For Regulating Production Of Interfering Ribonucleic Acid Patented View
18819737 Rnai Agents For Inhibiting Expression Of Inhibin Subunit Beta E (Inhbe), Pharmaceutical Compositions Thereof, And Methods Of Use Patented View
16649105 Expression Systems That Facilitate Nucleic Acid Delivery And Methods Of Use Abandoned View
16981052 In Situ Methods Of Inducing Of Immune Response Abandoned View
18977579 Composition For Regulating Production Of Interfering Ribonucleic Acid Patented View
18976118 Composition For Regulating Production Of Interfering Ribonucleic Acid Patented View
18976156 Composition For Regulating Production Of Interfering Ribonucleic Acid Patented View
18687072 Pnpla3-Targeting Short Interfering Rna (Sirna) Molecules And Uses Thereof Abandoned View
17781876 Sirna Conjugate, Double-Stranded Sirna Conjugate, Salt Thereof And Application Thereof Abandoned View
17415420 Methods Of Treatment And Diagnosis Of Tumours Abandoned View
18898720 Nucleic Acids For Inhibiting Expression Of Transferrin Receptor 2 Patented View
19036917 Antisense Polynucleotides To Induce Exon Skipping And Method Of Treating Dystrophies Abandoned View
17596753 Combination Of Hepatitis B Virus (Hbv) Vaccines And Hbv-Targeting Rnai Abandoned View
18928880 Cell Death-Inducing Dffa-Like Effector B (Cideb) Irna Compositions And Methods Of Use Thereof Patented View
16968861 Tumor Environment-Specific Expression Of Chimeric Antigen Receptors Abandoned View
17022678 Branched Lipid Conjugates Of Sirna For Specific Tissue Delivery Patented View
18723276 Compositions And Methods Of Trna Silencing Abandoned View
16754714 Methods And Compositions For Expansion Of Cell Population Patented View
17640706 Treatment Of Hr Deficient Cancer Abandoned View
18765286 Restoration Of The Cftr Function By Splicing Modulation Patented View
16951092 Immunomodulatory Therapeutic Mrna Compositions Encoding Activating Oncogene Mutation Peptides Abandoned View
16969314 Aptamer For Sclerostin And Use Thereof Patented View
18020329 Treatments For Retinal Degenerative Diseases Abandoned View
17040629 Crispr/cas9-Mediated Exon-Skipping Approach For Ush2a-Associated Usher Syndrome Patented View
17058989 Cytotoxic Fluoropyrimidine Polymers And Methods Of Use Thereof Patented View
17055378 Compositions And Methods For The Treatment Of Parkinson's Disease Patented View
17187018 Compounds And Methods For Modulating Smn2 Abandoned View
18264351 Use Of Mirna-485 Inhibitor To Regulate Psd95, Synaptophysin, And Caspase-3 Expression Abandoned View
17093225 Methods And Compositions For The Treatment Of Hepatic And Metabolic Diseases Abandoned View
17598150 Inhibition Of Monoamine Oxidase Subtype A (Maoa) Mitigates Cardiovascular Calcification Abandoned View
18036801 Chemical Modifications For Inhibiting Expression Of Aldh2 Abandoned View
18562787 Compositions And Methods For Silencing Carbonic Anhydrase 2 Expression Abandoned View
18741110 Antisense Oligonucleotide Targeting Atn1 Mrna Or Pre-Mrna Patented View
17547879 Oral Delivery Of Antisense Conjugates Targeting Pcsk9 Patented View
17417718 Treatment Of Spinal Conditions With Chimera Decoy Abandoned View
17266275 Systems And Methods For Aptamer-Based Intracellular Delivery Of A Payload Using Nanoneedles Abandoned View
18470687 Cftr-Modulating Compositions And Methods Patented View

Appeals Statistics

Purchase Subscription

Subscribe to Premium Examiner Statistics for unlimited access for your law firm.

Disclaimer: We do not provide any guarantees as to the accuracy of the statistics presented above and under
no circumstances will we be liable for any outcome resulting from your reliance on the above statistics.